Novavax, Inc.
NASDAQ:NVAXBiotechnology
Healthcare
$7.72 -1.84%
-$0.18 today
- Market cap
- $1.27B
- Beta
- 2.41
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.54
52W Low $6.13High $11.97
Volume 4.34M
Average 4.58M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$244.63M
FY 2025 · Annual
Investing Cash Flow
-$78.27M
FY 2025 · Annual
Financing Cash Flow
$27.74M
FY 2025 · Annual
-89.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.74B) | (657.94M) | (545.06M) | (187.5M) | 440.3M |
| Depreciation & Amortization | 12.66M | 29.05M | 41.23M | 48.5M | 27.61M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 183.63M | 130.3M | 85.36M | 48.15M | 36.02M |
| Change in Working Capital | 1.73B | (361.15M) | (376.84M) | 48.48M | (887.71M) |
| Accounts Receivables | (192.27M) | 249.17M | (274.44M) | 354.09M | 61.04M |
| Inventory | (600.33M) | (477.8M) | (74.46M) | 12.91M | (3.24M) |
| Accounts Payables | 600.33M | 913.4M | (378.81M) | (385.63M) | (322.57M) |
| Other Working Capital | 1.93B | (1.05B) | 350.87M | 67.11M | (622.94M) |
| Other Non-Cash Items | 136.79M | 443.8M | 81.35M | (44.89M) | 139.14M |
| Operating Cash Flow | 322.95M | (415.94M) | (713.97M) | (87.26M) | (244.64M) |
| Capital Expenditures | (57.49M) | (92.99M) | (58.81M) | (13.06M) | (5.56M) |
| Acquisitions (Net) | 57.49M | 0 | 0 | 192.64M | 0 |
| Purchases of Investments | (2.17M) | 0 | 0 | (825.59M) | (445.27M) |
| Sales of Investments | 159.81M | 0 | 0 | 443.55M | 353.74M |
| Other Investing Activities | (57.49M) | 0 | 0 | 0 | 18.83M |
| Investing Cash Flow | 100.15M | (92.99M) | (58.81M) | (204.04M) | (78.27M) |
| Debt Repayment | (127.91M) | 81.66M | (352.35M) | (3.99M) | 32.53M |
| Common Stock Issued | 564.86M | 249.23M | 360.24M | 263.27M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (4.8M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24.76M | (5.9M) | (3.59M) | 1.31M | 0 |
| Financing Cash Flow | 461.71M | 324.99M | 4.47M | 260.58M | 27.74M |
| Effect of Forex Changes | (5.29M) | 4.52M | 3.27M | (7.8M) | 5.93M |
| Net Change in Cash | 879.52M | (179.41M) | (765.04M) | (38.52M) | (289.24M) |
| Free Cash Flow | 265.46M | (508.92M) | (772.77M) | (100.32M) | (250.2M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$440.3M
+ D&A$27.6M
+ Stock-Based Comp$36.0M
+ Deferred Tax$0
- Working Capital-$887.7M
+ Other Non-Cash$139.1M
= Operating Cash Flow-$244.6M
- Capex-$5.6M
= Free Cash Flow-$250.2M
Analysis
FY2025 free cash flow is -$250.2M. FCF conversion is -56.8% of net income. Operating cash flow was -$244.6M, with capex of -$5.6M. The largest bridge item is Working Capital at -$887.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 16, 2026 |
Does NVAX generate free cash flow?
Novavax, Inc. (NVAX) generated -$250.19M of free cash flow in fiscal 2025.
How much operating cash flow does NVAX produce?
Operating cash flow was -$244.63M, before capital expenditures of $5.56M.
Continue the stock analysis
Jump to another research area for this company.